Top

Published in:

01-08-2019 | SHORT REPORT

An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent

Authors: Wang Yan, Chen Xiangyu, Li Ya, Wang Yu, Xu Feng

Published in: Investigational New Drugs | Issue 4/2019

Summary

Liver cancer is a kind of high mortality cancer due to the difficulty of early diagnosis. It is necessary to develop the anticancer agents to treat liver cancer. Here, a novel chalcone derivative was synthesized and evaluated for anticancer activity in vitro against liver cancer cell lines (HepG2, SNU-423, SMMC7221, and SNU-398). The chalcone hybrid 9 displayed the antiproliferative effect against HepG2, SNU-423, SMMC7221 and SNU-398 cells with IC₅₀ values of 0.9 μM, 2.7 μM, 6.2 μM and 4.6 μM, respectively. Cellular mechanisms showed that derivative 9 could obviously inhibit HepG2 cells growth and colony formation in a concentration-dependent manner. Analogue 9 inhibited the migration by regulating the expression levels of migration-releated markers and transcription factors (Snail and Slug). Tubulin polymerization inhibition assay illustrated that chalcone hybrid 9 might be a potent tubulin polymerization inhibitor. Importantly, compound 9 displayed the antitumor activity against liver cancer HepG2 cells in vivo with the low toxicity toward mice. Therefore, compound 9 as a novel tubulin polymerization inhibitor deserves further investigation to treat liver cancer.

Available only for authorised users

Yen CJ, Kim TY, Feng YH, Chao Y, Lin DY, Ryoo BY, Huang DCL, Schnell D, Hocke J, Loembé AB, Cheng AL (2018) A phase I/randomized phase II study to evaluate the safety, pharmacokinetics, and efficacy of Nintedanib versus Sorafenib in Asian patients with advanced hepatocellular carcinoma. Liver Cancer 7(2):165–178CrossRefPubMedPubMedCentral

Delord JP, Ravaud A, Bennouna J, Fumoleau P, Favrel S, Pinel MC, Ferré P, Saliba F (2013) Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction. Investig New Drugs 31(3):724–733. https://doi.org/10.1007/s10637-012-9878-7 CrossRef

Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM (2015) Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Investig New Drugs 33(4):911–920. https://doi.org/10.1007/s10637-015-0251-5 CrossRef

Zhang X, Zhang S, Sun Q, Jiao W, Yan Y, Zhang X (2018) Compound K induces endoplasmic reticulum stress and apoptosis in human liver Cancer cells by regulating STAT3. Molecules 23(6):1482CrossRefPubMedCentral

Piscaglia F, Ogasawara S (2018) Patient selection for Transarterial chemoembolization in hepatocellular carcinoma: importance of benefit/risk assessment. Liver Cancer 7(1):104–119CrossRefPubMedPubMedCentral

Szliszka E, Czuba ZP, Mazur B, Paradysz A, Krol W (2010) Chalcones and Dihydrochalcones augment TRAIL-mediated apoptosis in prostate Cancer cells. Molecules 15(8):5336–5353CrossRefPubMedPubMedCentral

Malek SNA, Phang CW, Ibrahim H, Abdul Wahab N, Sim KS (2011) Phytochemical and cytotoxic investigations of Alpinia mutica rhizomes. Molecules 16(1):583–589CrossRefPubMedPubMedCentral

Saxena HO, Faridi U, Kumar JK, Luqman S, Darokar MP, Shanker K, Chanotiya CS, Gupta MM, Negi AS (2007) Synthesis of chalcone derivatives on steroidal framework and their anticancer activities. Steroids 72(13):892–900. https://doi.org/10.1016/j.steroids.2007.07.012 CrossRefPubMed

Sashidhara KV, Kumar A, Kumar M, Sarkar J, Sinha S (2010) Synthesis and in vitro evaluation of novel coumarin–chalcone hybrids as potential anticancer agents. Bioorg Med Chem Lett 20(24):7205–7211. https://doi.org/10.1016/j.bmcl.2010.10.116 CrossRefPubMed

10.

Modzelewska A, Pettit C, Achanta G, Davidson NE, Huang P, Khan SR (2006) Anticancer activities of novel chalcone and bis-chalcone derivatives. Bioorg Med Chem 14(10):3491–3495. https://doi.org/10.1016/j.bmc.2006.01.003 CrossRefPubMed

11.

Ramirez-Tagle R, Escobar C, Romero V, Montorfano I, Armisén R, Borgna V, Jeldes E, Pizarro L, Simon F, Echeverria C (2016) Chalcone-induced apoptosis through caspase-dependent intrinsic pathways in human hepatocellular carcinoma cells. Int J Mol Sci 17(2):260CrossRefPubMedPubMedCentral

12.

Jandial D, Krill L, Chen L, Wu C, Ke Y, Xie J, Hoang B, Zi X (2017) Induction of G2M arrest by Flavokawain A, a kava Chalcone, increases the responsiveness of HER2-overexpressing breast Cancer cells to Herceptin. Molecules 22(3):462CrossRefPubMedCentral

13.

Liu M, Yin H, Qian X, Dong J, Qian Z, Miao J (2017) Xanthohumol, a Prenylated Chalcone from hops, inhibits the viability and stemness of doxorubicin-resistant MCF-7/ADR cells. Molecules 22(1):36CrossRef

14.

Yan J, Jie C, Zhang S, Hu J, Ling H, Li X (2016) Synthesis, evaluation, and mechanism study of novel indole-chalcone derivatives exerting effective antitumor activity through microtubule destabilization in vitro and in vivo. J Med Chem 59(11):5264–5283CrossRefPubMed

15.

Kakwani MD, Suryavanshi P, Ray M, Rajan MGR, Majee S, Samad A, Devarajan P, Degani MS (2011) Design, synthesis and antimycobacterial activity of cinnamide derivatives: a molecular hybridization approach. Bioorg Med Chem Lett 21(7):1997–1999. https://doi.org/10.1016/j.bmcl.2011.02.022 CrossRefPubMed

16.

Barbosa TP, Sousa SCO, Amorim FM, Rodrigues YKS, de Assis PAC, Caldas JPA, Oliveira MR, Vasconcellos MLAA (2011) Design, synthesis and antileishmanial in vitro activity of new series of chalcones-like compounds: a molecular hybridization approach. Bioorg Med Chem 19(14):4250–4256. https://doi.org/10.1016/j.bmc.2011.05.055 CrossRefPubMed

17.

Patra T, Ghosh P, Alam N, Murmu N (2018) Supra-physiological concentration of glyoxylate inhibits proliferation of human colon cancer cells through oxidative stress. Life Sci 207:80–89. https://doi.org/10.1016/j.lfs.2018.05.047 CrossRefPubMed

18.

Cevallos RR, Rodríguez-Martínez G, Gazarian K (2018) Wnt/β-catenin/TCF pathway is a phase-dependent promoter of Colony formation and Mesendodermal differentiation during human somatic cell reprogramming. Stem Cells 36:683–695CrossRefPubMed

19.

Chang TT, More SV, Lu IH, Hsu J-C, Chen T-J, Jen YC, Lu C-K, Li W-S (2011) Isomalyngamide A, A-1 and their analogs suppress cancer cell migration in vitro. Eur J Med Chem 46(9):3810–3819. https://doi.org/10.1016/j.ejmech.2011.05.049 CrossRefPubMed

20.

Özdemir A, Sever B, Altıntop M, Kaya Tilki E, Dikmen M (2018) Design, synthesis, and neuroprotective effects of a series of Pyrazolines against 6-hydroxydopamine-induced oxidative stress. Molecules 23(9). https://doi.org/10.3390/molecules23092151

21.

Rampa A, Bartolini M, Pruccoli L, Naldi M, Iriepa I, Moraleda I, Belluti F, Gobbi S, Tarozzi A, Bisi A (2018) Exploiting the Chalcone scaffold to develop multifunctional agents for Alzheimer’s disease. Molecules 23(8). https://doi.org/10.3390/molecules23081902

22.

Teng IJ, Tsai M-C, Shih S-F, Tsuei B-F, Chang H, Chuang Y-P, Lin C-S, Chern C-Y, Chen S-J (2018) Chalcone derivatives enhance ATP-binding cassette transporters A1 in human THP-1 macrophages. Molecules 23(7). https://doi.org/10.3390/molecules23071620

23.

Huang X, Shen Q-K, Zhang H-J, Li J-L, Tian Y-S, Quan Z-S (2018) Design and synthesis of novel Dehydroepiandrosterone analogues as potent Antiproliferative agents. Molecules 23(9). https://doi.org/10.3390/molecules23092243

24.

Kamal A, Shankaraiah N, Devaiah V, Laxma Reddy K, Juvekar A, Sen S, Kurian N, Zingde S (2008) Synthesis of 1,2,3-triazole-linked pyrrolobenzodiazepine conjugates employing ‘click’ chemistry: DNA-binding affinity and anticancer activity. Bioorg Med Chem Lett 18(4):1468–1473. https://doi.org/10.1016/j.bmcl.2007.12.063 CrossRefPubMed

25.

Kumar A, Ahmad I, Chhikara BS, Tiwari R, Mandal D, Parang K (2011) Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities. Bioorg Med Chem Lett 21(5):1342–1346. https://doi.org/10.1016/j.bmcl.2011.01.047 CrossRefPubMed

26.

Penthala NR, Madhukuri L, Thakkar S, Madadi NR, Lamture G, Eoff RL, Crooks PA (2015) Synthesis and anti-cancer screening of novel heterocyclic-(2H)-1,2,3-triazoles as potential anti-cancer agents. MedChemComm 6(8):1535–1543CrossRefPubMedPubMedCentral

27.

Kamal A, Prabhakar S, Janaki Ramaiah M, Venkat Reddy P, Ratna Reddy C, Mallareddy A, Shankaraiah N, Lakshmi Narayan Reddy T, Pushpavalli SNCVL, Pal-Bhadra M (2011) Synthesis and anticancer activity of chalcone-pyrrolobenzodiazepine conjugates linked via 1,2,3-triazole ring side-armed with alkane spacers. Eur J Med Chem 46(9):3820–3831. https://doi.org/10.1016/j.ejmech.2011.05.050 CrossRefPubMed

28.

Crous-Masó J, Palomeras S, Relat J, Camó C, Martínez-Garza Ú, Planas M, Feliu L, Puig T (2018) (−)-epigallocatechin 3-Gallate synthetic analogues inhibit fatty acid synthase and show anticancer activity in triple negative breast cancer. Molecules 23(5):1160CrossRefPubMedCentral

29.

Xiao M, Li M, Reynolds CS (2018) Colony formation in the cyanobacterium Microcystis. Biol Rev 93(3):1399–1420CrossRef

30.

Mori T, Doi R, Koizumi M, Toyoda E, Ito D, Kami K, Masui T, Fujimoto K, Tamamura H, Hiramatsu K (2004) CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther 3(1):29–37PubMed

31.

Li L, Su N, Zhou T, Zheng D, Wang Z, Chen H, Yuan S, Li W (2018) Mixed lineage kinase ZAK promotes epithelial–mesenchymal transition in cancer progression. Cell Death Dis 9(2):143. https://doi.org/10.1038/s41419-017-0161-x CrossRefPubMedPubMedCentral

32.

Chen H, Lin Z, Arnst K, Miller D, Li W (2017) Tubulin inhibitor-based antibody-drug conjugates for cancer therapy. Molecules 22(8):1281CrossRefPubMedCentral

33.

Kamal A, Kumar GB, Vishnuvardhan MVPS, Shaik AB, Reddy VS, Mahesh R, Sayeeda IB, Kapure JS (2015) Synthesis of phenstatin/isocombretastatin–chalcone conjugates as potent tubulin polymerization inhibitors and mitochondrial apoptotic inducers. Org Biomol Chem 13(13):3963–3981. https://doi.org/10.1039/C4OB02606C CrossRefPubMed

34.

Wang Q, Arnst KE, Wang Y, Kumar G, Ma D, Chen H, Wu Z, Yang J, White SW, Miller DD, Li W (2018) Structural modification of the 3,4,5-Trimethoxyphenyl moiety in the tubulin inhibitor VERU-111 leads to improved Antiproliferative activities. J Med Chem 61(17):7877–7891. https://doi.org/10.1021/acs.jmedchem.8b00827 CrossRefPubMed

Title: An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent
Authors: Wang Yan
Chen Xiangyu
Li Ya
Wang Yu
Xu Feng
Publication date: 01-08-2019
Publisher: Springer US
Published in: Investigational New Drugs / Issue 4/2019
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-019-00737-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 4/2019

Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial

Relationship between expression of XRCC1 and tumor proliferation, migration, invasion, and angiogenesis in glioma

Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma

CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia

Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1–ALK fusion: a case report

Phase II study of avelumab in multiple relapsed/refractory germ cell cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer